X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TPX-0005 (repotrectinib) is an oral ROS1/TKI inhibitor which is under phase 1/2 clinical development for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Bristol Myers Squibb gains a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis, including TPX-0005 (repotrectinib).
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $4,100.0 million Upfront Cash: $4,100.0 million
Deal Type: Acquisition August 17, 2022
Details:
TPX-0005 (repotrectinib) is small macrocyclic tyrosine kinase inhibitor of ROS1, TRK and ALK. Repotrectinib was designed to efficiently bind with the active kinase conformation and avoid steric interference from a variety of clinically resistant mutations.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zai Lab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
TPX-0005 (repotrectinib), is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
TPX-4589 (LM-302) is a potentially first-in-class anti-Claudin18.2 ADC discovered by LaNova that suppresses cell proliferation of gastric and pancreatic cell lines with nanomolar potency in preclinical models. It also has demonstrated efficacy in gastric and pancreatic cancer.
Lead Product(s): LM-302
Therapeutic Area: Oncology Product Name: TPX-4589
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: LaNova Medicines
Deal Size: $220.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement May 05, 2022
Details:
In TKI-naive patients for repotrectinib, in 71 total patients, there was a cORR of 79% across global trial. Ten of 11 patients responded within China for a cORR of 91% and DOR ranged from 3.6+ to 7.5+ months with a median duration of follow-up of 3.7 months.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zai Lab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Enrollment target of 40 patients achieved for expansion cohort 6 (EXP-6) for TPX-0005 (repotrectinib), a next-generation kinase inhibitor targeting the ROS1 and TRK in NTRK-positive TKI-pretreated advanced solid tumors.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The primary objective of the Phase 2 portion of the study is to determine the anti-tumor activity of repotrectinib in pediatric and young adult patients less than 25 years old.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
Details:
Repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. TRIDENT-1 study showed Repotrectinib was most potent inhibitor of wild-type TRKA/B/C fusions than selitrectinib.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
Repotrectinib, and elzovantinib (TPX-0022), a novel MET/SRC/CSF1R inhibitor and a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.
Lead Product(s): TPX0022
Therapeutic Area: Oncology Product Name: TPX-0022
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
